Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? (Q37870216)

From Wikidata

Jump to navigation Jump to search

scientific article published on 02 May 2011

Language	Label	Description	Also known as
English	Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?	scientific article published on 02 May 2011

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21529310%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference

Europe PubMed Central

Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21529310%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

0 references

brain metastasis

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21529310%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Michele Caraglia

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21529310%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

Raffaele Addeo

1

1 reference

Europe PubMed Central

24 August 2017

Michele Caraglia

2

1 reference

Europe PubMed Central

24 August 2017

language of work or name

0 references

publication date

2 May 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21529310%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21529310%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21529310%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21529310%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

881-895

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21529310%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Radiation-induced dementia in patients cured of brain metastases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Radiotherapy in small-cell lung cancer: where should it go?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Current management of brain metastases, with a focus on systemic options

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Response of brain metastases from breast cancer to systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

The role of chemotherapy in brain metastases.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Multidisciplinary management of brain metastases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

A phase II trial of temozolomide for patients with recurrent or progressive brain metastases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Temozolomide for treating brain metastases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Therapy and prophylaxis of brain metastases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Metastatic pattern of malignant melanoma. A study of 216 autopsy cases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

PARP inhibitor development for systemic cancer targeting

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Bevacizumab safety in patients with central nervous system metastases.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.580736

21 January 2018

Identifiers

10.1517/13543784.2011.580736

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21529310%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21529310%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37870216&oldid=1745988449"